Nascent Biotech, Inc. (NBIO)
OTCMKTS: NBIO · Delayed Price · USD
0.0500
-0.0050 (-9.09%)
Jul 26, 2024, 3:47 PM EDT - Market closed
Nascent Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.61M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 379.49B |
| Johnson & Johnson | 81.80B |
| Merck & Co. | 61.40B |
| AbbVie | 54.40B |
| Novartis AG | 48.86B |
| AstraZeneca | 47.61B |
| Thermo Fisher | 42.49B |
| Abbott Laboratories | 40.33B |
NBIO News
- 3 months ago - Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run - Accesswire
- 4 months ago - Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System - Accesswire
- 6 months ago - Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates - Accesswire
- 7 months ago - Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued - Accesswire
- 7 months ago - Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk - Accesswire
- 8 months ago - Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier - Accesswire
- 1 year ago - Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer - Accesswire
- 1 year ago - Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting - Accesswire